AstraZeneca and GSK have announced separate agreements with China's Sino Biopharm, reinforcing a growing trend of cross-border pharmaceutical partnerships. AstraZeneca licensed an investigational respiratory medicine, while GSK expanded its commercial collaboration in China. The announcements come as regulators increasingly examine
